Survival in Patients with Acute Lymphoblastic Leukemia and COVID-19 in Mexico
International Blood Research & Reviews,
Aims: To determine the survival of patients with acute lymphoblastic leukemia and COVID-19.
Study Design: Prospective, analytical and relational.
Place and Duration of Study: Hematology department, Hospital of Specialties, High Specialty Medical Unit, National Medical Center "Gral. Manuel Avila Camacho", Puebla, Mexico, during the period June 2020-April 2021
Methodology: Patients aged 15 to 64 years, both sexes, with acute lymphoblastic leukemia and a confirmed diagnosis of COVID-19 by PCR. The variables included were; sex, age (groups: 15-20; 21-29; 30-39; 40-49; 50-59; and 60-64), comorbidities, general treatment and hematological treatment response. Survival was determined for the diagnosis of COVID-19 for 11 months, using the Kaplan Meier estimator and the Log-Rak test; Cox regression model (univariate and multivariate); as well as Chi square and V-Cramer with a 95% confidence interval and using the statistical program SPSS Ver. 25.
Results: The study consisted of 20 patients, of which 33.3% were women, with an average age of 37.75 ± 11.63 years; The men registered an age of 28.50 ± 18.05 years. Overall survival was 50%, with a lower limit of 101.3 and an upper limit of 242.5 days, with a mean of 171.9 days; and median at 17 days. No significant differences were found in survival regarding sex, comorbidities, general treatment and hematological response. However, mortality in patients with comorbidities was higher (p = 0.051).
Conclusion: Survival in patients with acute lymphoblastic leukemia and COVID-19 is low, due to complications that increase mortality, mainly owing to hematological suppression, and even more so with the presence of comorbidities.
- hematological alterations
How to Cite
Inaba H, Pei D, Wolf J, Howard SC, Hayden RT, Go M, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Annals of Oncology. 2017; 28(2):386-392.
Rendón MME, Reyes ZNC, Villasís KMÁ, Meneses JS, Núñez AE. Global trend of survival in pediatric acute lymphoblastic leukemia: a review of the last four decades. Boletín Médico del Hospital Infantil de México. 2012:69(3):153-163.
Sánchez LMM, Jaramillo LIJ, Hernández LFÁ, Restrepo FH, Mejía CR, Álzate JDV. Residual minimal disease: breaking the paradigm of complete remission. Revista Cubana de Hematología, Inmunología y Hemoterapia. 2018;34(1):21-32.
Shchelkanov MY, Popova AY, Dedkov VG, Akimkin VG, Maleyev VV. History of investigation and current classification of coronaviruses (Nidovirales: Coronaviridae). Russian Journal of Infection and Immunity. 2020;10(2):221-246.
Shchelkanov MY, Kolobukhina LV, Burgasova OA, Kruzhkova IS, Maleev VV. COVID-19: etiology, clinical picture, treatment. Russian Journal of Infection and Immunity. 2020;10(3):421-445.
Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomedical journal. 2020;43(4):328-333.
Coronavirus Resource Center. World Map. Jhons Hopkins University; 2021.
Accessed 14 march 2021.
COVID-19 México. General information. Health Secretary; 2021.
Accessed 14 march 2021.
Van der Plas E, Qiu W, Nieman BJ, Yasui Y, Liu Q, Dixon SB, et al. Sex-Specific Associations Between Chemotherapy, Chronic Conditions, and Neurocognitive Impairment in Acute Lymphoblastic Leukemia Survivors: A Report From the Childhood Cancer Survivor Study. Journal of the National Cancer Institute. 2020;djaa136.
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354-2363. DOI: 10.1038/s41375-020-0959-x.
Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, et al. Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy. Leukemia. 2020;34(9):2531-2532.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/metabolism research and reviews. 2020; 36(7):e3319.
Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V. Borlenghi E., et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126(23):5069-5076.
Borah P, Mirgh S, Sharma SK, Bansal S, Dixit A, Dolai TK, et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells, Molecules, and Diseases. 2021;87: 102525.
García SJ, De La Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. Journal of hematology & oncology. 2020; 13(1):1-12.
Abstract View: 847 times
PDF Download: 294 times